270 related articles for article (PubMed ID: 30099860)
1. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
[TBL] [Abstract][Full Text] [Related]
3. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
[TBL] [Abstract][Full Text] [Related]
4. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
6. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
Li Q; Liu M; Ma F; Luo Y; Cai R; Wang L; Xu N; Xu B
PLoS One; 2014; 9(8):e104870. PubMed ID: 25137071
[TBL] [Abstract][Full Text] [Related]
7. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
8. Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment.
Chekhun VF; Borikun TV; Bazas VМ; Andriiv AV; Klyusov OМ; Yalovenko TМ; Lukianova NY
Exp Oncol; 2020 Sep; 42(3):162-166. PubMed ID: 32996748
[TBL] [Abstract][Full Text] [Related]
9. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
[TBL] [Abstract][Full Text] [Related]
10. Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients.
Ibrahim AM; Said MM; Hilal AM; Medhat AM; Abd Elsalam IM
Tumour Biol; 2020 Oct; 42(10):1010428320963811. PubMed ID: 33028151
[TBL] [Abstract][Full Text] [Related]
11. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.
Wu X; Somlo G; Yu Y; Palomares MR; Li AX; Zhou W; Chow A; Yen Y; Rossi JJ; Gao H; Wang J; Yuan YC; Frankel P; Li S; Ashing-Giwa KT; Sun G; Wang Y; Smith R; Robinson K; Ren X; Wang SE
J Transl Med; 2012 Mar; 10():42. PubMed ID: 22400902
[TBL] [Abstract][Full Text] [Related]
12. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
14. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
[No Abstract] [Full Text] [Related]
15. The correlation of circulating pro-angiogenic miRNAs' expressions with disease risk, clinicopathological features, and survival profiles in gastric cancer.
Peng W; Liu YN; Zhu SQ; Li WQ; Guo FC
Cancer Med; 2018 Aug; 7(8):3773-3791. PubMed ID: 30003708
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Robelin P; Tod M; Colomban O; Lachuer J; Ray-Coquard I; Rauglaudre G; Joly F; Chevalier-Place A; Combe P; Lortholary A; Hamizi S; Raban N; Ferron G; Meunier J; Berton-Rigaud D; Alexandre J; Kaminsky MC; Dubot C; Leary A; Malaurie E; You B
Gynecol Oncol; 2020 Oct; 159(1):256-263. PubMed ID: 32712155
[TBL] [Abstract][Full Text] [Related]
17. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
Li M; Zhou Y; Xia T; Zhou X; Huang Z; Zhang H; Zhu W; Ding Q; Wang S
Breast Cancer Res Treat; 2018 Jul; 170(2):257-270. PubMed ID: 29557526
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.
Frères P; Josse C; Bovy N; Boukerroucha M; Struman I; Bours V; Jerusalem G
J Cell Physiol; 2015 Feb; 230(2):473-81. PubMed ID: 25078559
[TBL] [Abstract][Full Text] [Related]
20. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
Dalmasso B; Hatse S; Brouwers B; Laenen A; Berben L; Kenis C; Smeets A; Neven P; Schöffski P; Wildiers H
BMC Cancer; 2018 Oct; 18(1):1014. PubMed ID: 30348127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
